Clinical Characteristics and Rationality of Medication among IgA Nephropathy Outpatients in a Rehabilitation Center

doi:10.19803/j.1672-8629.2021.09.19

Abstract

Abstract: Objective To find out about the drug composition, characteristics of medication and rationality of prescriptions among patients with IgA nephropathy so as to provide reference for clinical rational drug use. Methods From January 1, 2018 to December 31, 2019, 18 6111 prescriptions for nephrotic outpatients and 809 148 medication orders were collected, including 4 326 prescriptions and 13 542 medication orders for IgA nephropathy. The drug categories, dosage and composition of different drug categories specified in prescriptions for IgA nephropathy were statistically analyzed. Results The proportion of traditional Chinese medicine and Chinese patent medicine was much higher than that of chemical medicine and western medicine (78.4% vs 21.6%). Chinese patent medicine was mainly used for IgA nephropathy, supplemented by drugs that could invigorate the spleen and kidney, clear heat and detoxification, and tonify the lung and kidney. Chemical medicine and western medicine were mainly used to reduce proteinuria and blood pressure. It was found that there were 73 improper prescriptions, accounting for 1.7% of the total, which were mainly manifested as nonstandard prescription writing and prescriptions of inappropriate drugs. Conclusion Traditional Chinese medicine is combined with western medicine in the treatment of IgA nephropathy in our hospital, and medication is basically well-grounded. The proportion of traditional Chinese medicine and traditional Chinese patent medicine is high, but there are cases of irrational medication. It is critical to keep an eye on prescriptions and standardize clinical medications.

Key words: nephropathy, IgA nephropathy, outpatients, medication analysis

CLC Number:

R969.3

SHEN Jingping. Clinical Characteristics and Rationality of Medication among IgA Nephropathy Outpatients in a Rehabilitation Center[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 883-886.

References

[1] Ghosh S, Das S, et al.Enumerating the role of properdin in the pathogenesis of IgA nephropathy and its possible therapies[J].International Immunopharmacology, 2021, 28(3): 205-218.
[2] Zhen A, Ming L. Lowα-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction[J]. Science Translational Medicine, 2016, 8(345): ra88.
[3] Lu J, Li MM.Research progress of urinary exosome microRNAs in kidney diseases[J]. Chinese Journal of Pathophysiology(中国病理生理杂志), 2020,36(2):378-384.
[4] Ou YY, Xie JY.Progress in genetic mechanism of IgA nephropathy[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2020, 40(7): 529-532.
[5] Ishiko S, Tanaka A, Takeda A, et al.Utility of glomerular Gd-IgA1 staining for indistinguishable cases of IgA nephropathy or Alport syndrome[J]. Clinical and Experimental Nephrology, 2021(9): 1-9.
[6] Fan PP, Tian Y.Research progress of traditional Chinese and Western medicine in the treatment of IgA nephropathy[J]. China Medical Herald(中国医药导报), 2019, 28: 44-47.
[7] Hu TT, Xu F.Pareto diagram analysis of irrational drug use prescriptions in outpatient department of a 3A hospital[J], Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(6): 366-376.
[8] Zheng X, Zhang CR.Analysis of hypertension characteristics and related risk factors in IgA nephropathy patients[J]. China Journal of Modern Medicine(中国现代医学杂志), 2019, 29(5): 53-58.
[9] Ai SN, Wang YX, Sun WW, et al.Wang Yaoxian's experience in treating IgA nephropathy from rheumatism[J], China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2021, 36(1): 236-239.
[10] Li JZ.Curative effect analysis of traditional Chinese medicine and integrated traditional Chinese and western medicine in the treatment of 150 cases of IgA nephropathy[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2014, 6(14): 88-89.
[11] Floege J, Eitner F.Current therapy for IgA nephropathy[J]. J Am Soc Nephrol, 2011, 22(10): 1785-1794.
[12] The standardization project group of the guideline for clinical application of Chinese patent medicine in the treatment of dominant diseases. Guidelines for clinical application of Chinese patent medicine in the treatment of chronic kidney disease stage 3-5 (non dialysis) (2020)[J]. Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志),2021, 41(3): 261-271.
[13] Wu J, Duan SW, Yang HT, et al.Efficacy and safety of Shen-yankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: a multicenter randomized controlled trial[J]. Journal of Integrative Medicine, 2021, 19(2): 111-119.
[14] Zhao P, Yang M, Deng MM.The research progress of pharmacology of natural Cordyceps sinensis and Fermented Cordyceps powder in recent 5 years[J]. Drug Evaluation(药品评价), 2020, 17(19): 5-8.
[15] Sun XP.Research progress of Fermented Cordyceps powder in the treatment of respiratory diseases[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine(现代中西医结合杂志), 2019, 28(23): 2608-2612.
[16] Sun XP.Research progress of Fermented Cordyceps powder in the treatment of kidney disease[J]. International Journal of Urology and Nephrology(国际泌尿系统杂志), 2019 (3): 562-565.
[17] Zhou HX.Therapeutic effect of Bailing capsule on hematuria of IgA nephropathy[J], Traditional Chinese Medicinal Research(中医研究), 2002,15(4): 26-27.
[18] Lu WJ.Huangkui capsule combined with valsartan tablets in the treatment of IgA nephropathy with mild to moderate proteinuria[J], Basic medical forum(基层医学论坛),2020,24(16): 2287-2289.